"Dr Reddy"
Latest news and video coverage curated from trusted media outlets
0 shares | ShareTweetSavePostSend |
You Might Like
Zambon Taps Kinaxis to Enhance Transparency Across Global Supply Chain*Business Wire India*Kinaxis^® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced Zambon, a multinational pharmaceutical company committed to innovating cure..Business Wire India - Published | |
INVNT Scales South Asia Presence with Breakthrough Brand Activations, Immersive Storytelling, and Cultural-First Experiences*Business Wire India*INVNT®, the global live brand storytelling agency, is accelerating its presence across South Asia and redefining what it means to build culture through creativity. Since opening..Business Wire India - Published | |
Dr Reddy's receives two USFDA observations for New York API facilityDr. Reddy's Laboratories faced USFDA scrutiny at its New York API facility, receiving a Form 483 with two observations after a GMP inspection concluded on May 16, 2025. The company will address these..IndiaTimes - Published | |
SBI, NTPC Green Energy, Yes Bank, IndusInd Bank, Adani Power, Swiggy, Dr. Reddy's Share Price in FocusTopNews - Published | |
Dr Reddy’s Q4 net profit rises 21% to Rs 1,587 crore on strong global salesDr. Reddy's Laboratories announced a 21% surge in net profit, reaching Rs 1,587 crore for the March 2025 quarter, fueled by strong sales in the US and India. Annual profit saw a modest 3% rise to Rs..IndiaTimes - Published | |
'Factually incorrect': Dr Reddy's denies report on 25 pc workforce cost cuts, laying off highly-paid staffnewKerala.com - Published | |
Pharma co Dr Reddy's to reduce costsIndiaTimes - Published | |
Dr Reddy's cuts workforce cost by 25 pc, lays off employees above Rs 1 cr package: ReportnewKerala.com - Published Also reported by •Zee News | |
'Factually incorrect': Dr. Reddy clears air amid workforce reduction rumorsDr. Reddy's Laboratories has refuted media reports alleging a 25% reduction in workforce costs. The Hyderabad-based pharmaceutical giant dismissed claims of layoffs targeting high-earning employees and..IndiaTimes - Published | |
Dr Reddy's layoffs: Pharma firm cuts workforce cost by 25 per cent, asks even senior employees earning Rs 1 crore to quitEmployees in the age group of 50-55 years working in Dr Reddy's research and development (R&D) division have been offered a voluntary retirement, a report said. The pharma company currently has a..DNA - Published | |
Dr Reddy's inks South East Asia commercialisation, licence pacts with China's Bio-Thera for Stelara, Simponi biosimilarsIndiaTimes - Published | |
Dr Reddy's Q3 PAT rises 2% despite 16% jump in revenuesIndiaTimes - Published | |
Dr Reddy's Q3 profit up 2% at Rs 1,413 crore; revenue at Rs 8,359 croreDr Reddy's Laboratories saw a 2% rise in consolidated net profit to Rs 1,413 crore in Q3 FY24, driven by strong market performance. Revenue grew to Rs 8,359 crore, with notable growth in the US,..IndiaTimes - Published | Sensex, Nifty end on a positive note on first trading session of 2025![]() Mid-Day - Published |
Meet man with Rs 26858 crore net worth, runs Rs 104268 crore company, his business is...Dr. Reddy's daughters: Preetha, Suneeta, Shobana, and Sangita now take the reins of the business, and his careful mentorship is part of the process.DNA - Published | Dr Reddy launches world's 1st immuno-onco drug for nasopharyngeal cancer in IndiaDr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare head..IndiaTimes - Published |
Aurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucelDr Reddy’s Laboratories' subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India's first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene..IndiaTimes - Published | Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug LenacapavirDr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120..IndiaTimes - Published |
'Madhabi Buch investing in Chinese firms': Congress ups ante against Sebi chiefCongress has accused Sebi chief Madhabi Puri-Buch of making high-value investments in Chinese firms during geopolitical tensions and trading in listed securities with unpublished price-sensitive..IndiaTimes - Published | Hindenburg Research alleges SEBI chief Madhabi Puri Buch's firm illegally accepted payments from listed entitiesHindenburg named Mahindra & Mahindra, ICICI Bank, Dr Reddy's Laboratories, and Pidilite Industries as among the companies that allegedly paid the consulting firm.DNA - Published |
IIM Mumbai Unveils Plans for Rs. 800 Crore State-of-the-Art Facilities for Students and Innovation![]() NewsVoir - Published | TEDx Marwadi University Inspires Students with a 'Kaleidoscope of Ideas'![]() NewsVoir - Published |
Dr Reddy’s Labs most valued family business from TelanganaThe 2024 Barclays Private Clients and Hurun India rankings revealed that the Prasad and Reddy family of Dr Reddy's Laboratories topped as the most valuable family business from Telangana, valued at Rs..IndiaTimes - Published | Dr Reddy's invests Rs 734 crore in JV with Nestle IndiaDr Reddy's Laboratories invested over Rs 734 crore for a 51% stake in a joint venture with Nestle India, which invested Rs 705.6 crore for the remaining 49%. The JV focuses on health and nutrition..IndiaTimes - Published |
Dr Reddy’s Rituximab biosimilar Ituxredi gets EMA CHMP positive recommendationDr Reddy’s Laboratories announced that the EMA’s committee recommended its Rituximab biosimilar Ituxredi for the European market. The decision will be reviewed by the European Commission for final..IndiaTimes - Published | Higher tax outgo dents Dr Reddy’s Q1 net profitIndiaTimes - Published |
Dr Reddy’s to buy UK company's nicotine gum business for Rs 5,000 croreDr Reddy's Laboratories is set to acquire Haleon Plc's NRT business, including Nicotinell, for GBP 500 million. The deal encompasses various NRT formats and potential contingent payments. This..IndiaTimes - Published | Dr Reddy's Q4 net profit up 36%IndiaTimes - Published |
Dr Reddy’s initiates voluntary recall of Sapropterin Dihydrochloride in US over potency concernsIndiaTimes - Published | Dr Reddy’s rolls out migraine management device Nerivio in EuropeIndiaTimes - Published |
Dr Reddy's to exclusively distribute Sanofi's vaccine portfolio in IndiaDr Reddy’s Laboratories on Wednesday informed the bourses has entered into an exclusive partnership with Sanofi Healthcare India Pvt Ltd for the distribution of the latter’s vaccine portfolio in..IndiaTimes - Published | Dr Reddy's ties up with US firm for resuscitative therapyIndiaTimes - Published |
Megha, Yashoda hospital, pharma companies kept BRS in good healthMEIL was the biggest donor to BRS with Rs 195 crore. Yashoda Hospital followed with Rs 94 crore. Dr Reddy’s Lab and Hetero Drugs contributed Rs 32 crore and Rs 30 crore, respectively.IndiaTimes - Published | BJP, BRS & Cong top recipients of donations from pharma firmsBJP, BRS, Congress dominated pharma donations through electoral bonds, with BJP receiving the highest amount. Aurobindo Pharma, whose director was arrested in an excise scam, is also one of the donors..IndiaTimes - Published |
Booster shot: Sector biggies to make Uttar Pradesh a pharma hubDr Reddy’s Laboratory, Rockwell Automation, and other Telangana pharmaceutical companies plan to invest in Uttar Pradesh. They are attracted by the pro-pharma policies of the Yogi government. The..IndiaTimes - Published | Pharma, Healthcare Stocks Top Sectoral Gainers In TradeSun Pharma is the top Sensex gainer with gains of more than 3 per cent. Dr Reddy's is up more than 4 per cent. Max Healthcare is up 6 per cent.Zee News - Published |
Dr Reddy’s acquires MenoLabs women’s wellness portfolio from AmyrisDr Reddy's Laboratories acquires Amyris Inc's MenoLabs portfolio, a women's health and dietary supplement brand, as part of Amyris' Chapter 11 bankruptcy sales proceedings. The acquisition includes..IndiaTimes - Published | United States: BPCIA Complaint Against Proposed Rituxan® Biosimilar DRL_RI Filed - Venable LLPOn November 17, 2023, Genentech, Inc., Hoffmann-La Roche Inc., and Biogen Inc. ("Plaintiffs") filed a BPCIA complaint ("Complaint") against Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories SA..Mondaq - Published |
Dr Reddy's becomes sole Indian pharma player to make it to Dow Jones Sustainability World Index 2023Dr Reddy's Laboratories becomes the first and only Indian pharma company on the S&P Dow Jones Sustainability World Index for 2023. The company also retains its position on the Dow Jones Sustainability..IndiaTimes - Published | Pharma faces USFDA heat, stocks downThe stocks of several pharma companies, including Dr Reddy's, Aurobindo Pharma, Cipla, Lupin, Sun Pharma, and Divi's Labs, have been lagging behind as the sensex and Nifty reach new highs. Dr Reddy's..IndiaTimes - Published |
Dr Reddy's inks pact with Coya Therapeutics for investigational ALS therapy COYA 302Dr Reddy's Laboratories SA, a subsidiary of Dr Reddy's Laboratories, has signed a development and licence agreement with Coya Therapeutics Inc for the development and commercialisation of COYA 302, a..IndiaTimes - Published | Experts Urge for Preventive Lifestyle and Awareness on Treatment Options at the Osteoporosis Awareness SummitThe experts at the Osteoporosis Awareness Summit observed that osteoporosis is a public health emergency, however early screening and preventive lifestyle can help in proactive management and effective..NewsVoir - Published |
Dr Reddy's Bachupally biologics facility gets USFDA Form 483 with 9 observationsOn Thursday, Dr. Reddy's Laboratories, a prominent pharmaceutical company, disclosed to the stock exchanges that it has been issued a Form 483 containing nine observations by the US Food & Drug..IndiaTimes - Published | India: Delhi High Court Rules In Favour Of Reddy's Laboratories On Use Of The Mark RAZOFAST By Fast Cure Pharma - LexOrbisIn the recent case of Dr. Reddy's Laboratories Ltd vs Fast Cure Pharma, the plaintiff applied to the Delhi High Court for a permanent injunction restraining the defendant from manufacturing...Mondaq - Published |